Currently browsing

octubre 14, 2020

Letermovir for prevention of cytomegalovirus reactivation in haploidentical and mismatched adult donor allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide for graft-versus-host disease prophylaxis

Cytomegalovirus (CMV) is serious viral infection in allogeneic hematopoietic cell transplantation (allo HCT) recipients. November 2017, the novel CMV DNA terminase complex inhibitor letermovir was approved for prophylaxis of CMV infection in CMV-seropositive allo HCT recipients. Here, we sought to determine the effectiveness of letermovir in preventing CMV infection in CMV-seropositive patients undergoing haploidentical or mismatched adult unrelated donor allo HCT using post-transplant…

Antibody-based strategies in HIV therapy.

Antibody-based strategies in HIV therapy.
Int J Antimicrob Agents. 2020 Oct 09;:106186
Authors: Kufel WD
Antibody-based strategies have been introduced for a number of disease states, but r…